» Articles » PMID: 37666813

Stromal Cells in the Tumor Microenvironment: Accomplices of Tumor Progression?

Overview
Journal Cell Death Dis
Date 2023 Sep 4
PMID 37666813
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment (TME) is made up of cells and extracellular matrix (non-cellular component), and cellular components include cancer cells and non-malignant cells such as immune cells and stromal cells. These three types of cells establish complex signals in the body and further influence tumor genesis, development, metastasis and participate in resistance to anti-tumor therapy. It has attracted scholars to study immune cells in TME due to the significant efficacy of immune checkpoint inhibitors (ICI) and chimeric antigen receptor T (CAR-T) in solid tumors and hematologic tumors. After more than 10 years of efforts, the role of immune cells in TME and the strategy of treating tumors based on immune cells have developed rapidly. Moreover, ICI have been recommended by guidelines as first- or second-line treatment strategies in a variety of tumors. At the same time, stromal cells is another major class of cellular components in TME, which also play a very important role in tumor metabolism, growth, metastasis, immune evasion and treatment resistance. Stromal cells can be recruited from neighboring non-cancerous host stromal cells and can also be formed by transdifferentiation from stromal cells to stromal cells or from tumor cells to stromal cells. Moreover, they participate in tumor genesis, development and drug resistance by secreting various factors and exosomes, participating in tumor angiogenesis and tumor metabolism, regulating the immune response in TME and extracellular matrix. However, with the deepening understanding of stromal cells, people found that stromal cells not only have the effect of promoting tumor but also can inhibit tumor in some cases. In this review, we will introduce the origin of stromal cells in TME as well as the role and specific mechanism of stromal cells in tumorigenesis and tumor development and strategies for treatment of tumors based on stromal cells. We will focus on tumor-associated fibroblasts (CAFs), mesenchymal stem cells (MSCs), tumor-associated adipocytes (CAAs), tumor endothelial cells (TECs) and pericytes (PCs) in stromal cells.

Citing Articles

A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study.

Lin Y, Sun Y, Li C, Zhang Y, Zhang R, Wang S Ann Hematol. 2025; .

PMID: 40087153 DOI: 10.1007/s00277-025-06299-w.


Ex.50.T aptamer impairs tumor-stroma cross-talk in breast cancer by targeting gremlin-1.

Quintavalle C, Ingenito F, Roscigno G, Pattanayak B, Esposito C, Affinito A Cell Death Discov. 2025; 11(1):94.

PMID: 40069570 PMC: 11897156. DOI: 10.1038/s41420-025-02363-6.


Tumor cell-derived EMP1 is essential for cancer-associated fibroblast infiltration in tumor microenvironment of triple-negative breast cancer.

Wang Q, Li D, Ma H, Li Z, Wu J, Qiao J Cell Death Dis. 2025; 16(1):143.

PMID: 40016223 PMC: 11868485. DOI: 10.1038/s41419-025-07464-9.


Association of Plasma Lipid Patterns and LDL Cholesterol Levels with Breslow Thickness and Ulceration in Melanoma Patients.

Szasz I, Koroknai V, Varvolgyi T, Pal L, Szucs S, Piko P Int J Mol Sci. 2025; 26(4).

PMID: 40004177 PMC: 11855400. DOI: 10.3390/ijms26041716.


Systematic inference of super-resolution cell spatial profiles from histology images.

Zhang P, Gao C, Zhang Z, Yuan Z, Zhang Q, Zhang P Nat Commun. 2025; 16(1):1838.

PMID: 39984438 PMC: 11845739. DOI: 10.1038/s41467-025-57072-6.


References
1.
Aboulkheyr Es H, Zhand S, Thiery J, Warkiani M . Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020; 12(7):188-197. DOI: 10.1093/intbio/zyaa014. View

2.
Wen D, Liang T, Chen G, Li H, Wang Z, Wang J . Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy. Adv Sci (Weinh). 2022; 10(5):e2206001. PMC: 9929126. DOI: 10.1002/advs.202206001. View

3.
Zhang T, Lee Y, Rui Y, Cheng T, Jiang X, Li G . Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther. 2013; 4(3):70. PMC: 3707041. DOI: 10.1186/scrt221. View

4.
Cui G, Liu H, Laugsand J . Endothelial cells-directed angiogenesis in colorectal cancer: Interleukin as the mediator and pharmacological target. Int Immunopharmacol. 2022; 114:109525. DOI: 10.1016/j.intimp.2022.109525. View

5.
Giordo R, Wehbe Z, Paliogiannis P, Eid A, Mangoni A, Pintus G . Nano-targeting vascular remodeling in cancer: Recent developments and future directions. Semin Cancer Biol. 2022; 86(Pt 2):784-804. DOI: 10.1016/j.semcancer.2022.03.001. View